Trial Profile
Phase I study of weekly amrubicin in patients with refractory or relapsed lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 May 2008
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 07 May 2008 New trial record.